NICE | October 2019 | Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer [ID1485]
NICE has announced it has approved the medication for ovarian cancer- rucaparib- can now be offered to women with relapsed ovarian, fallopian tube or peritoneal cancer, that has responded to platinum-based chemotherapy. Taken as a tablet, twice daily, it slows the progression of cancer by preventing cancer cells repairing so slowing down the tumour’s growth.
Around 1,350 people in England could benefit from this new treatment which will be available immediately through the CDF.
This approval is a change from the committee’s initial decision, where uncertainties in the evidence, and the price of rucaparib, meant it could not be recommended for routine use on the NHS.
Clinical trial evidence shows that rucaparib prevents cancer progression for twice as long as the placebo treatment (median of 10.8 months in the rucaparib group compared with 5.4 months in the placebo group). However, it is not known how this will translate into overall extended life expectancy due to incomplete trial data.
The drug company has since proposed an alternative price for rucaparib. If this revised commercial arrangement is supported with long-term overall survival data, rucaparib has the potential to be a cost-effective use of NHS resources. The committee therefore decided to include rucaparib in the CDF to allow this long-term data to be collected (Source: NICE).
The guidance is expected to be published on 13 November 2019.
Read the press release here
In the news: